GLP1R and metabolic dysfunction-associated steatotic liver disease: In conclusion, our meta-analysis is the most comprehensive and updated assessment of placebo-controlled and active-controlled RCTs of individuals with NAFLD, using different GLP-1 RAs to specifically treat NAFLD or NASH.